Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?

Taking stock of the drug industry, from the lab to the medicine chest

August 19, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Carsten Snejbjerg/Bloomberg STAT+ | Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants? Will a complicated deal to buy a contract drugmaker clear FTC review? Novo target Catalent also makes some of Eli Lilly's best-selling drugs. By Ed Silverman STAT+ | AI drug firm Recursion seeks to move from survival to industry domination Recursion will release proof-of-concept clinical trial data over the next 12 months; investor interest in seeing if AI can speed drug development is high. By Allison DeAngelis STAT+ | Peter Orszag wants the FTC and DOJ to stop challenging 'vertical' health care mergers The Lazard CEO, one of the architects of the ACA, makes the case for vertical integration of health care, which reaps rewards for his firm. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser